Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study
The DOI matches its Crossref record, with a small difference in title or year; 30 of the 30 references it cites were found in a registry or an index.
Abstract
To examine metabolic changes (lipids, liver enzymes, blood pressure, and weight) potentially associated with conversion to diabetes, we analyzed serial glucose and other metabolic measures obtained every 6 months within the West of Scotland Coronary Prevention Study trial. Changes in parameters for 86 men who converted to new-onset diabetes (“converters”: two consecutive glucose levels ≥7 mmol/l) were compared with 860 “nonconverters” matched for age and treatment allocation. Eighteen months before the diagnosis, converters to diabetes had elevated (P < 0.01) fasting glucose, weight, triglyceride, alanine aminotransferase (ALT), blood pressure, and white cell count and lower HDL cholesterol compared with nonconverters. The mean (SD) increase in fasting glucose over 18 months in converters was 1.80 (1.52) mmol/l, compared with 0.10 (0.57) in nonconverters. Of parameters measured, only ALT (P = 0.0005) and triglyceride (P = 0.030) increased significantly more over the 18 months in converters compared with nonconverters, but neither parameter increased significantly in nonconverters with high baseline glucose concentrations (>6.1 mmol/l). Finally, only sustained increases in ALT predicted a higher risk for diabetes. We conclude that a relatively rapid rise in fasting glucose levels is frequent in converters to diabetes and that associated increases over time in ALT and potentially triglyceride suggest hepatic fat accumulation as a contributing factor for conversion to diabetes in men at risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from epidemiological studies with repeated measures of glucose and insulin parameters over many years suggests that the development of T2DM is a gradual process 54, 55.”
From Type 2 diabetes mellitus and psychological stress — a modifiable risk factor (2017) · cites this paper as [54]
In the citing paper
“As evidenced by studies with repeat measures of glucose levels, insulin sensitivity and insulin secretion, the development of diabetes from NGT is a continuous process.35,36,40,41”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [35]
In the citing paper
“This pattern of glycaemic changes was confirmed by others.35,40,41”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [35]
In the citing paper
“Most recent attempts to improve diabetes prediction using measurements from genetics and transcriptomics have not shown significant improvements in predictive performance but it is unknown whether serial measurements may decrease variations in non-genetic biomarkers allowing for a more precise estimation of their levels.34–36”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [35]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 1×
“With respect to drug treatment, glitazones lower hepatic fat directly and lower liver enzyme levels (24,25), in particular ALT, as observed in the rosiglitazone arm of the recently reported DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) study (26), whereas metformin has been variably…”
BackgroundSattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000080897.52664.94 · Cited by 1,506 · cited 1×
“Such information, in conjunction with extensive baseline measures, has allowed us to link baseline metabolic syndrome status (5), C-reactive protein (6), and From the (1)Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland; the (2)Robertson Centre for Biostatistics, University of Glasgow, Glas…”
BackgroundSelf-citationMechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322 · cited 1×
“Excess fat in liver, via accumulation of total fatty acyl-CoA, impairs insulinstimulated IRS-1 and IRS-2 tyrosine phosphorylation and ultimately decreases insulin activation of glycogen synthase and promotes increased gluconeogenesis (16).”
BackgroundPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911 · cited 1×
“(20) noted that moderate weight loss with very low–fat diet normalizes fasting hyperglycemia in patients with poorly controlled type 2 diabetes by mobilizing a relatively small pool of intrahepatic lipid.”
BackgroundEffect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737 · cited 1×
“Finally, although ramipril did not significantly reduce progression to diabetes in subjects at risk, it did significantly increase regression to normoglycemia and was associated with a significantly greater reduction in ALT concentrations in the 1st year compared with placebo (29).”
BackgroundFreeman, D. J., Norrie, J., Caslake, M. J., Gaw, A., Ford, I., Lowe, G. D. O., O’Reilly, D. S. J., Packard, C. J., Sattar, N., & for the West of Scotland Coronary Prevention Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.5.1596 · Cited by 728 · cited 1×
“Such information, in conjunction with extensive baseline measures, has allowed us to link baseline metabolic syndrome status (5), C-reactive protein (6), and From the (1)Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland; the (2)Robertson Centre for Biostatistics, University of Glasgow, Glas…”
BackgroundSelf-citationVozarova, B., Stefan, N., Lindsay, R. S., Saremi, A., Pratley, R. E., Bogardus, C., & Tataranni, P. A. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1889 · Cited by 717 · cited 1×
“However, because cholesterol is not generally predictive of diabetes and because others have shown higher ALT levels to predict diabetes (8,10,11), we feel such limitations are not significant concerns.”
BackgroundBugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691 · cited 1×
“With respect to drug treatment, glitazones lower hepatic fat directly and lower liver enzyme levels (24,25), in particular ALT, as observed in the rosiglitazone arm of the recently reported DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) study (26), whereas metformin has been variably…”
Background
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60619-x · Cited by 898
Fatty Liver: A Novel Component of the Metabolic Syndrome
Kotronen, A., & Yki-Järvinen, H. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 797
Modeling type 2 diabetes in rats using high fat diet and streptozotocin
Skovsø, S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12235 · Cited by 596
From the metabolic syndrome to NAFLD or vice versa?
Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Järvinen, H., & Svegliati-Baroni, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.016 · Cited by 497
Taylor, R. (2013) · Diabetes Care · doi:10.2337/dc12-1805 · Cited by 485
Type 2 diabetes mellitus and psychological stress — a modifiable risk factor
Hackett, R. A., & Steptoe, A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.64 · Cited by 480
Obesity-Associated Liver Disease
Marchesini, G., Moscatiello, S., Di Domizio, S., & Forlani, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1399 · Cited by 359
Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause
Taylor, R. (2008) · Diabetologia · doi:10.1007/s00125-008-1116-7 · Cited by 352
“The clearest prospective information of the time course to development of type 2 diabetes comes from the West of Scotland Coronary Prevention Study [38].”
InfluentialKotronen, A., Juurinen, L., Tiikkainen, M., Vehkavaara, S., & Yki–Järvinen, H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.021 · Cited by 339
Freathy, R. M., Timpson, N. J., Lawlor, D. A., Pouta, A., Ben-Shlomo, Y., Ruokonen, A., Ebrahim, S., Shields, B., Zeggini, E., Weedon, M. N., et al. (2008) · Diabetes · doi:10.2337/db07-1466 · Cited by 316
Understanding the mechanisms of reversal of type 2 diabetes
Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30076-2 · Cited by 299
Self-citationPreiss, D., & Sattar, N. (2008) · Clinical Science · doi:10.1042/cs20070402 · Cited by 292
Self-citationFatty liver index and mortality: The cremona study in the 15th year of follow-up
Calori, G., Lattuada, G., Ragogna, F., Garancini, M. P., Crosignani, P., Villa, M., Bosi, E., Ruotolo, G., Piemonti, L., & Perseghin, G. (2011) · Hepatology · doi:10.1002/hep.24356 · Cited by 253
“NAFLD is associated with an increased risk of developing advanced fibrosis and cirrhosis(3) and incident type 2 diabetes.(4) Because of its association with metabolic syndrome and type 2 diabetes, it has been hypothesized that NAFLD may also be associated with increased rates of cardiovascular disease (CVD)(5); in par…”
BackgroundGender aspects in type 2 diabetes mellitus and cardiometabolic risk
Sattar, N. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.006 · Cited by 177
Self-citationNovel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?
Sattar, N., Wannamethee, S. G., & Forouhi, N. G. (2008) · Diabetologia · doi:10.1007/s00125-008-0954-7 · Cited by 143
“Similarly, we demonstrated that increases in ALT and triacylglycerol, over an 18 month period, accompanied progression to type 2 diabetes in men at risk, whereas weight, blood pressure, HDL-cholesterol, and white cell count, although higher at baseline, did not show significantly greater increases over time in men who…”
BackgroundSelf-citationMonami, M., Bardini, G., Lamanna, C., Pala, L., Cresci, B., Francesconi, P., Buiatti, E., Rotella, C. M., & Mannucci, E. (2008) · Metabolism · doi:10.1016/j.metabol.2007.10.015 · Cited by 148
“Alanine aminotransferase (ALT) is also associated with incident diabetes [3,9,11-13,17,18], although to a lesser extent than γ-GT [3,9,12], whereas aspartate aminotransferase (AST)”
BackgroundSteven, S., & Taylor, R. (2015) · Diabetic Medicine · doi:10.1111/dme.12722 · Cited by 132
Cummings, B. P., Digitale, E., Stanhope, K. L., Graham, J. L., Baskin, D. G., Reed, B. J., Sweet, I. R., Griffen, S. C., & Havel, P. J. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90635.2008 · Cited by 123
Vreman, R. A., Goodell, A. J., Rodríguez, L. A., Porco, T. C., Lustig, R. H., & Kahn, J. G. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013543 · Cited by 123
“10 21–23 24–27 It is important to identify determinants of these metabolic diseases and assess the efficacy of upstream policy interventions to curb the national and the global epidemic of metabolic syndrome.”
BackgroundBanting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes
Taylor, R. (2013) · Diabetic Medicine · doi:10.1111/dme.12039 · Cited by 107
Musso, G., Gambino, R., Pacini, G., De Michieli, F., & Cassader, M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26720 · Cited by 107
Færch, K., Witte, D. R., Tabák, Á. G., Perreault, L., Herder, C., Brunner, E. J., Mika Kivimaki, B., & Vistisen, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70008-1 · Cited by 121
Qian, K., Zhong, S., Xie, K., Yu, D., Yang, R., & Gong, D. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2655 · Cited by 121
Hulmán, Á., Simmons, R. K., Brunner, E. J., Witte, D. R., Færch, K., Vistisen, D., Ikehara, S., Kivimäki, M., & Tabák, Á. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4275-6 · Cited by 113
Type 2 diabetes and remission: practical management guided by pathophysiology
Taylor, R. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13214 · Cited by 105
Henney, A. E., Gillespie, C. S., Alam, U., Hydes, T. J., & Cuthbertson, D. J. (2023) · Nutrients · doi:10.3390/nu15102266 · Cited by 74
Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data
Mavrogiannaki, A. N., & Migdalis, I. N. (2013) · International Journal of Endocrinology · doi:10.1155/2013/450639 · Cited by 104
“…Pomerania,” Germany, to assess the relation of fatty liver disease to self-reported health care utilization and costs at baseline and 5 years, in a general population cohort study of 4310 adults aged 20 to 79 years at baseline, subjects with NAFLD and increased serum ALT levels, after controlling…”
BackgroundUnderstanding the cause of type 2 diabetes
Taylor, R. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00157-8 · Cited by 95
Tsuchida, T., Shiraishi, M., Ohta, T., Sakai, K., & Ishii, S. (2011) · Metabolism · doi:10.1016/j.metabol.2011.10.023 · Cited by 89
Jiang, F., Yan, H., Liang, L., Du, J., Jin, S., Yang, S., Wang, H., Hu, T., Zhu, Y., Wang, G., et al. (2021) · Liver International · doi:10.1111/liv.14896 · Cited by 79
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T. M., Preiss, D., Sattar, N. A., Fraser, A., & Waugh, N. R. (2011) · Health Technology Assessment · doi:10.3310/hta15380 · Cited by 81
Self-citationHou, X., Zhu, Y., Lu, H., Chen, H., Li, Q., Jiang, S., Xiang, K., & Jia, W. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06509.x · Cited by 79
Janssen, J. A. M. J. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105488 · Cited by 253
The potential of novel biomarkers to improve risk prediction of type 2 diabetes
Herder, C., Kowall, B., Tabák, Á. G., & Rathmann, W. (2013) · Diabetologia · doi:10.1007/s00125-013-3061-3 · Cited by 81
Unnikrishnan, R., Shaw, J. E., Chan, J. C. N., Wild, S. H., Peters, A. L., Orrange, S., Roden, M., & Mohan, V. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00635-0 · Cited by 76
“Several other cohorts have reported similar phenomena 45–47 with variations amongst ethnic groups exhibiting different time course patterns of these changes 48”
Miller, A. M., Purves, D. G., McConnachie, A., Asquith, D. L., Batty, G. D., Burns, H., Cavanagh, J., Ford, I., McLean, J. S., Packard, C. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047830 · Cited by 66
“Elevated levels of ALT and GGT are associated with T2D independent of other factors [21,22,23].”
Self-citationStrategies for preventing type 2 diabetes: an update for clinicians
Khavandi, K., Amer, H., Ibrahim, B., & Brownrigg, J. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313494986 · Cited by 62
“This is illustrated by longitudinal studies [Sattar et al. 2007; Tabak et al. 2009; Mason et al. 2007], which show glucose values tightly regulated until 2–6 years before diagnosis, at which point there is a sharp increase.”
MethodPrediabetes: The Importance of Early Identification and Intervention
Hsueh, W. A., Orloski, L., & Wyne, K. L. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2180 · Cited by 71
“diabetes, with hepatic fat accumulation as a potential contributing factor for the conversion.(56) Regarding postprandial glucose metabolism, reports suggest substantial heterogeneity among prediabetic individuals(57) and different risk factors for postprandial hyperglycemia in men versus women.”
BackgroundThe Role of Non-Alcoholic Fatty Liver Disease in Cardiovascular Disease
Perseghin, G. (2010) · Digestive Diseases · doi:10.1159/000282088 · Cited by 59
“Association of Surrogate Markers of NAFLD with the Onset of Type 2 Diabetes MellitusEven though it should be kept in mind that liver enzymes as ‘surrogate measures’ of liver fat are far from perfect, an increasing amount of epidemiological reports suggest that NAFLD is associated with incident type 2 diabetes. In part…”
BackgroundHeianza, Y., Arase, Y., Fujihara, K., Hsieh, S. D., Saito, K., Tsuji, H., Kodama, S., Yahagi, N., Shimano, H., Yamada, N., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1793 · Cited by 56
“We found that trajectories of FPG during development of diabetes were comparable to those reported previously (7,8).”
ResultPark, E. Y., Lim, M. K., Oh, J., Cho, H., Bae, M. J., Yun, E. H., Kim, D., & Shin, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063439 · Cited by 51
“Previous studies have suggested that increased liver enzymes levels may also predict type 2 diabetes and cardiovascular disease independent of other potential risk factors, such as obesity and alcohol consumption [8,9,10].”
BackgroundCassidy, S., Hallsworth, K., Thoma, C., MacGowan, G. A., Hollingsworth, K. G., Day, C. P., Taylor, R., Jakovljević, D. G., & Trenell, M. I. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0187-2 · Cited by 56
Sattar, N. A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03480.x · Cited by 60
Self-citationScirica, B. M. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255539 · Cited by 55
Lipids in the Wrong Place: Visceral Fat and Nonalcoholic Steatohepatitis
Perseghin, G. (2011) · Diabetes Care · doi:10.2337/dc11-s249 · Cited by 46
“In particular, sustained and nontransient ALT elevations were found to be associated with type 2 diabetes (25).”
BackgroundImpact of non‐alcoholic fatty liver disease on accelerated metabolic complications
Fan, J. (2008) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2008.00323.x · Cited by 45
Role of Serum Adiponectin and Vitamin D in Prediabetes and Diabetes Mellitus
Banerjee, A., Khemka, V. K., Roy, D., Poddar, J., Roy, T. K. S., & Karnam, S. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.10.006 · Cited by 47
Reversal and Remission of T2DM – An Update for Practitioners
Shibib, L., Al-Qaisi, M., Ahmed, A., Miras, A. D., Nott, D., Pelling, M., Greenwald, S. E., & Guess, N. D. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s345810 · Cited by 48
High risk of cardiovascular disease in iron overload patients
Meroño, T., Rosso, L. A. G., Sorroche, P. B., Boero, L. E., Arbelbide, J. A., & Brites, F. D. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02429.x · Cited by 43
Preiss, D., Sattar, N., Harborne, L., Norman, J., & Fleming, R. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01825.x · Cited by 39
Self-citationLiu, Z., Que, S., Ning, H., Wang, L., & Peng, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080596 · Cited by 40
Chronic Microvascular Complications in Prediabetic States—An Overview
Baranowska-Jurkun, A., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103289 · Cited by 43
Alvarsson, M., Hilding, A., & Östenson, C. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02685.x · Cited by 36
Mahrooz, A., Parsanasab, H., Hashemi‐Soteh, M. B., Kashi, Z., Bahar, A., Alizadeh, A., & Mozayeni, M. (2014) · Clinical and Experimental Medicine · doi:10.1007/s10238-014-0283-8 · Cited by 34
Malmström, H., Walldius, G., Carlsson, S., Grill, V., Jungner, I., Guðbjörnsdóttir, S., Kosiborod, M., & Hammar, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13241 · Cited by 35
Decreased gene expression of insulin signaling genes in insulin sensitive tissues of obese cats
Mori, A., Lee, P., Takemitsu, H., Iwasaki, E., Kimura, N., Yagishita, M., Hayasaka, M., & Arai, T. (2008) · Veterinary Research Communications · doi:10.1007/s11259-008-9179-y · Cited by 32
“It has been suggested that an increase in plasma TG and ALT may be associated with hepatic fat accumulation and fatty liver diseases (Iacobellis et al. 2008; Sattar et al. 2007).”
BackgroundInvestigation and management of hypertriglyceridaemia
Ferns, G. A., Keti, V., & Griffin, B. A. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.055756 · Cited by 38
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
Bizzotto, R., Jennison, C., Jones, A. G., Kurbasic, A., Tura, A., Kennedy, G., Bell, J. D., Thomas, E. L., Frost, G. S., Eriksen, R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1567 · Cited by 33
Buday, B., Pach, F. P., Literáti-Nagy, B., Vitai, M., Kovács, G., Vecsei, Z., Koranyi, L. I., & Lengyel, C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0222-3 · Cited by 29
Pathophysiology of Prediabetes Hyperinsulinemia and Insulin Resistance in the Cardiovascular System
Bkaily, G., Jazzar, A., Abou-Aichi, A., & Jacques, D. (2025) · Biomedicines · doi:10.3390/biomedicines13081842 · Cited by 29
“This process supports fat storage while inhibiting lipolysis, leading to high fat accumulation and obesity [36,37].”
Pinnaduwage, L., Ye, C., Hanley, A. J., Connelly, P. W., Sermer, M., Zinman, B., & Retnakaran, R. R. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00306 · Cited by 26
Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment
Lonardo, A., Caldwell, S. H., & Loria, P. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.5 · Cited by 25
Jiamjarasrangsi, W., Sangwatanaroj, S., Lohsoonthorn, V., & Lertmaharit, S. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.01.009 · Cited by 25
Rankin, N., Preiss, D., Welsh, P. I., & Sattar, N. A. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw271 · Cited by 26
“As previous data had linked ALT levels to liver fat, these serial data were amongst the first to suggest that hepatic fat accumulation may increase before diabetes development.(33) Such repeated measure datasets and biobanks provide excellent resources to better understand the evolution of novel metabolomics pathways,…”
ResultSelf-citationRoncero‐Ramos, I., Gutierrez-Mariscal, F. M., Gómez-Delgado, F., Villasanta‐Gonzalez, A., Torres-Peña, J. D., de la Cruz, S., Rangel-Zúñiga, O. A., Luque, R. M., Ordovás, J. M., Delgado‐Lista, J., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.07.001 · Cited by 27
Heianza, Y., Arase, Y., Kodama, S., Tsuji, H., Tanaka, S., Saito, K., Hara, S., & Sone, H. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12308 · Cited by 26
Calorie restriction and reversal of type 2 diabetes
Taylor, R. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1239525 · Cited by 25
“achieved by Sattar and colleagues [12].”
Murillo‐Villicaña, M., Noriega‐Cisneros, R., Peña‐Montes, D. J., Huerta‐Cervantes, M., Méndez, A. A., Cortés‐Rojo, C., Salgado‐Garciglia, R., Montoya-Pérez, R. D. C., Riveros‐Rosas, H., & Saavedra‐Molina, A. (2022) · Nutrients · doi:10.3390/nu14091946 · Cited by 23
Anemaet, I. G., Metón, I., Salgado, M. C. D. O., Fernández, F., & Baanante, I. V. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.05.018 · Cited by 24
Sattar, N., McGuire, D. K., & Gill, J. M. R. (2022) · Circulation · doi:10.1161/circulationaha.122.060411 · Cited by 19
Self-citationSalgado, M. C. D. O., Metón, I., Anemaet, I. G., & Baanante, I. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.01.005 · Cited by 21
Hulsegge, G., Spijkerman, A. M. W., van der Schouw, Y. T., Bakker, S. J. L., Gansevoort, R. T., Smit, H. A., & Verschuren, W. M. M. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.23 · Cited by 19
Metabolic dysfunction-related liver disease as a risk factor for cancer
Taylor, A., Siddiqui, M. K., Ambery, P., Armisen, J., Challis, B., Haefliger, C., Pearson, E. R., Doney, A. S. F., Dillon, J. F., & Palmer, C. N. A. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000817 · Cited by 18
El-Gharib, M., FARAHAT, M. N. M. R., Mahfouz, A., & Morad, M. A. (2013) · Journal of Basic and Clinical Reproductive Sciences · doi:10.4103/2278-960x.112582 · Cited by 22
“Most attempts to substantially improve diabetes prediction with measurements from genetics and transcriptomics have not been successful, and whether serial measurements might decrease variations in non-genetic biomarkers, resulting in a more precise estimation of their concentrations, is not known.[22-24]”
BackgroundJohansson, H.-E., Haenni, A., & Zethelius, B. (2011) · Journal of Obesity · doi:10.1155/2011/273105 · Cited by 17
“Hindawi Publishing Corporation Journal of Obesity Volume 2011, Article ID 273105, 6 pages doi:10.1155/2011/273105”
InfluentialJohansson, H.-E., Haenni, A., Karlsson, F. A., Engström, B. E., Öhrvall, M., Sundbom, M., & Zethelius, B. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0102-6 · Cited by 16
“disease (NAFLD) and liver fat content which also reflects the glucometabolic status [ 34 ].”
BackgroundJiamjarasrangsi, W., Lohsoonthorn, V., Lertmaharit, S., & Sangwatanaroj, S. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.008 · Cited by 16
Fatty liver score and 15-year incidence of type 2 diabetes
Kotronen, A., Laaksonen, M. A., Heliövaara, M., Reunanen, A., Tuomilehto, J. O., Yki‐Järvinen, H., Peltonen, M., & Knekt, P. (2013) · Hepatology International · doi:10.1007/s12072-013-9430-7 · Cited by 16
Alanine transferase: An independent indicator of adiposity related comorbidity risk in youth
Klein, M. L., Iazzetti, L., Speiser, P., Carey, D. E., Shelov, S. P., Accacha, S. D., Fennoy, I., ROSENBAUM, M. S., & Rapaport, R. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12221 · Cited by 14
DeBoer, M. D., Lin, B., Filipp, S. L., Cusi, K. J., & Gurka, M. J. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.12.023 · Cited by 15
“Prior studies have noted reciprocal relationships between MetS and NAFLD, with elevations in ALT levels preceding development of diabetes independent of weight change[30] and individuals with MetS exhibiting systemic inflammation and hepatocyte dysfunction that contribute to worsening NAFLD[31].”
BackgroundGautier, A., Roussel, R., Lange, C., Piguel, X., Cauchi, S., Vol, S., Froguel, P., Balkau, B., & Bonnet, F. (2011) · Diabetes · doi:10.2337/db10-1442 · Cited by 13
“7 Treatment for hypertension, n (%) 15 (22) 19 (19) 0.”
BackgroundTagawa, H., Irie, J., Itoh, A., Kusumoto, Y., Kato, M., Kobayashi, N., Tanaka, K., Morinaga, R., Fujita, M., Nakajima, Y., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.025 · Cited by 12
PROLEGOMENON TO THE EUROPEAN CONSTITUTION BOOK OF DIABETES MELLITUS
Ionescu-Tirgoviste, C., & Paulescu, N. (2008) · Cited by 13
Johansson, H.-E., Haenni, A., Öhrvall, M., Sundbom, M., & Zethelius, B. (2009) · Obesity Surgery · doi:10.1007/s11695-009-9806-x · Cited by 11
“Serum ALT and triglyceride concentrations increase and HDL cholesterol decreases gradually before onset of T2DM [ 34 ].”
BackgroundTransactivation of cytosolic alanine aminotransferase gene promoter by p300 and c-Myb
Anemaet, I. G., González, J. D., Salgado, M. C. D. O., Giralt, M., Fernández, F., Baanante, I. V., & Metón, I. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0022 · Cited by 13
“In addition, a rise of serum Alt activity within the reference values in healthy populations is considered a marker for the development of insulin resistance and type 2 diabetes (Vozarova et al. 2002, Hanley et al. 2004, West et al. 2006, Sattar et al. 2007).”
BackgroundKim, M., Cho, Y. K., Jung, C. H., & Lee, W. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111125 · Cited by 10
Sokup, A., & Barbara, R. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000138 · Cited by 9
Zhyzhneuskaya, S. V., & Taylor, R. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_21-1 · Cited by 8
Ahmadi, N., Valizadeh, M., Hadaegh, F., Mahdavi, M., Tasdighi, E., Azizi, F., & Khalili, D. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13205 · Cited by 7
(2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805361211201010039 · Cited by 8
Narankiewicz, D., Ruiz-Nava, J., Buonaiuto, V. A., Ruiz-Moreno, M. I., Lopez-Carmona, M. D., Perez-Belmonte, L. M., Gómez‐Huelgas, R., & Bernal-López, M. R. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103518 · Cited by 7
“Moreover, there is significant interobserver variability and difficulties in its use in obese subjects [51].”
BackgroundZhyzhneuskaya, S. V., Al‐Mrabeh, A. H., Peters, C., Barnes, A. C., Hollingsworth, K. G., Welsh, P., Sattar, N., Lean, M. E. J., & Taylor, R. (2025) · Diabetic Medicine · doi:10.1111/dme.15462 · Cited by 6
“23,24 These changes are reflected in the 5-year follow-up data from DiRECT.”
Self-citationThe role of the liver in insulin resistance
Lanthier, N. (2014) · Digital Access to Libraries · Cited by 7
Transitional features of histologic type of non‐alcoholic fatty liver disease in Korean young men
Kim, J. K., Chon, N. R., Lim, H. C., Lee, K. S., Han, K., Chon, C. Y., Park, Y. N., & Paik, Y. H. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06895.x · Cited by 6
Wannamethee, S. G., & Sattar, N. A. (2010) · Diabetes Care · doi:10.2337/dc09-2239 · Cited by 5
“It is important to remember that our data also suggest a diet high in fiber may protect from type 2 diabetes via attenuating or preventing hepatic fat accumulation, an increasingly recognized feature in the pathogenesis of diabetes (3,4).”
BackgroundSelf-citationJiamjarasrangsi, W., Lertmaharit, S., Sangwatanaroj, S., & Lohsoonthorn, V. (2009) · PubMed · Cited by 5
Fatty liver disease, glucose tolerance and insulin resistance in obese adolescents
Slyper, A. H., Rosenberg, H., Kabra, A., Huang, W. ‐., Blech, B., & Matsumura, M. M. (2014) · Pediatric Obesity · doi:10.1111/ijpo.279 · Cited by 4
“found that this was associated with a rise in ALT and triglyceride, also suggesting hepatic fat accumulation as a contributing factor to diabetes (7).”
BackgroundWhy Early, Large-scale Weight Loss Is the Future of Type 2 Diabetes Care
Sattar, N. A., & Buse, J. B. (2025) · Diabetes Care · doi:10.2337/dci25-0069 · Cited by 5
Self-citationTranscriptomics und Typ-2-Diabetes
Herder, C., Roden, M., Carstensen, M., Illig, T., & Prokisch, H. (2012) · Der Diabetologe · doi:10.1007/s11428-011-0777-x · Cited by 3
Metadata
- Authors
- Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C.
- Affiliations
- University of Glasgow (GB)
- Stobhill Hospital (GB)
- MRC Epidemiology Unit (GB)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-04-01
- Volume
- 56
- Issue
- 4
- Pages
- 984-991
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2103040969
- Cited by
- 127
- References
- 30
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 7 · 2013: 11 · 2012: 9
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- type 2 diabetes, prediabetes, fasting blood glucose, alanine aminotransferase, triglycerides, hepatic lipid accumulation, liver enzymes, diabetes risk prediction, men, WOSCOPS, HDL cholesterol, blood pressure, body weight
- MeSH terms
- Adipose Tissue, Alanine Transaminase, Aspartate Aminotransferases, Blood Glucose, Body Weight, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Lipids, Liver, Male, Scotland, Triglycerides, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.